---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-029394"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-24T00:07:13.544643+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD Q2 net income $112.3M; revenue $28.6M (+24% YoY); ANNOVERA sales double

## Summary
- Net revenue $28.6M, up 24% YoY; net income $112.3M ($12.83 basic EPS) vs net loss $42.7M in Q2 2021.
- ANNOVERA revenue $18.3M, up 91% YoY; 9,329 TRx (+28% YoY); over 13,000 prescribing HCPs (+65%).
- Operating expenses fell 21% to $42.7M; debt reduced to $90.8M after repaying $125M in 2022.
- Cash $26.3M plus $11.3M restricted; vitaCare divestiture gain $143.4M.
- FDA approved sNDA for ANNOVERA; CEO highlights focus on women's health.

## SEC filing metadata
- accession: 0001564590-22-029394
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000156459022029394/0001564590-22-029394-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000156459022029394/txmd-8k_20220815.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-029394
- JSON: https://secwatch.observer/filing/0001564590-22-029394.json
- Plain text: https://secwatch.observer/filing/0001564590-22-029394.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.